The Development of Tissue Engineering Scaffolds Using Matrix from iPS-Reprogrammed Fibroblasts.pdf (934.23 kB)
Download file

The development of tissue engineering scaffolds using matrix from iPS-reprogrammed fibroblasts.

Download (934.23 kB)
journal contribution
posted on 22.06.2022, 14:45 by Francesco Santarella, Fergal O'BrienFergal O'Brien, Jonathan A Garlick, Cathal KearneyCathal Kearney
Tissue engineering solutions have been widely explored for enhanced healing of skin wounds. Diabetic foot ulcers (DFU) are particularly challenging wounds to heal for a variety of reasons, including aberrant ECM, dysregulation of vascularization, and persistent inflammation. Tissue engineering approaches, such as porous collagen-based scaffolds, have shown promise in replacing the current treatments of surgical debridement and topical treatments. Collagen-glycosaminoglycan scaffolds, which are FDA approved for diabetic foot ulcers, can benefit from further functionalization by incorporation of additional signaling factors or extracellular matrix molecules. One option for this is to incorporate matrix from a rejuvenated cell source, as wounds in younger patients heal more quickly. Induced pluripotent stem cells (iPS) are generated from somatic cells and share many functional similarities with embryonic stem cells (ES), while avoiding the ethical concerns. Fibroblasts differentiated from iPS cells have been shown to enrich their ECM with glycosaminoglycan (GAGs), collagen Type III and fibronectin, to have an increased ECM production, and to be pro-angiogenic. Here we describe a technique to grow matrix from post-iPS fibroblasts, and to develop a scaffold from this matrix, in combination with collagen, with the goal of enhancing wound healing. By activating scaffolds with extracellular matrix (ECM) from fibroblasts derived from an iPS source (post-iPSF), the scaffolds are enriched with beneficial elements like GAGs, collagen type III, fibronectin, and VEGF. We believe these scaffolds can enhance skin regeneration and that the techniques can be modified for other tissue engineering applications.

History

Comments

The original article is available at https://link.springer.com/

Published Citation

Santarella F, O'Brien FJ, Garlick JA, Kearney CJ. The development of tissue engineering scaffolds using matrix from iPS-reprogrammed fibroblasts. Methods Mol Biol. 2022;2454:273-283.

Publication Date

24 Mar 2021

PubMed ID

33755908

Department/Unit

  • Amber (Advanced Material & Bioengineering Research) Centre
  • Tissue Engineering Research Group (TERG)
  • Anatomy and Regenerative Medicine

Research Area

  • Immunity, Infection and Inflammation
  • Chemistry and Pharmaceutical Sciences
  • Biomaterials and Regenerative Medicine

Publisher

Springer US

Version

  • Accepted Version (Postprint)